Eyenovia, Inc. provided an update on April 10, 2025, regarding the development of its novel Optejet User Filled Device (UFD). The company announced the completion of several Verification & Validation (V&V) studies for the device.
Completed V&V parameters include dose accuracy, spray pattern, plume geometry, and device integrity. These studies are crucial to ensure the device meets standards for intended use and customer requirements.
Eyenovia remains on track for a 510(k) submission for the Optejet UFD as early as September 2025. The user-filled Optejet is designed to work with various topical ophthalmic liquids, such as artificial tears and lens rewetting products, targeting multi-billion dollar markets.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.